Status | Study |
Active, not recruiting |
Study Name: 131I-rituximab for Relapsed or Refractory Marginal Zone B-cell Lymphoma Condition: Relapsed or Refractory Marginal Zone B-cell Lymphoma Date: 2012-09-04 Interventions: Drug: 131I-rituximab |
Completed |
Study Name: Endomicroscopy and Gastric MALT-lymphoma Condition: MALT-lymphoma Date: 2012-01-08 Interventions: Procedure: Confocal laser endomicroscopy |
Active, not recruiting |
Study Name: R-CVP for the Treatment of Non-conjunctival Ocular Adnexal MALT Lymphoma (OAML) Condition: Lymphoma Date: 2011-08-30 Interventions: Drug: rituximab, cyclophosphamide, vincristine, and prednisolone 6 cycles of R-CVP followed by 2 cycles |
Completed |
Study Name: Prognostic Study of Gastric MALT Lymphoma After Eradication of Helicobacter Pylori Condition: Gastric Low-grade MALT Lymphoma With Helicobacter Pylori Positive Date: 2010-12-20 Interventions: Drug: Rabeprazole Sodium The following 3 drugs are taken o |
Completed |
Study Name: Multicenter Phase II Study to Evaluate the Clinical Activity and the Safety Profile of Everolimus in Marginal Zone B-cell Lymphomas (MZL) Condition: Marginal Zone B-cell Lymphoma Date: 2010-07-15 Interventions: Drug: Everolimus Everolimus (tablets, 5 mg) is given orally at the dose of 10 mg/day from day 1 to day 2 |
Terminated |
Study Name: Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma Condition: Follicular Lymphoma Marginal Zone Lymphoma Date: 2010-02-11 Interventions: Drug: azacitidine Azacitidine |
Not yet recruiting |
Study Name: Trial of Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type Condition: MALT Lymphoma Date: 2009-06-17 Interventions: Drug: Lenalidomide 25 mg Lenalidomide p.o. daily for 21 days |
Completed |
Study Name: Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma Condition: Marginal Zone Lymphoma Date: 2007-03-27 Interventions: Drug: Rituximab IV Infusion of |
Active, not recruiting |
Study Name: Involved Field Radiotherapy for Non-gastric Marginal Zone Lymphoma Condition: Non-gastric Marginal Zone Lymphoma Date: 2006-09-14 Interventions: Radiation: Involved Field Radiotherapy The prescribed dose |
Completed |
Study Name: Velcade in MALT Lymphoma Patients Condition: MALT Lymphoma Date: 2006-09-07 Interventions: Drug: Bortezomib (Velcade) |